Prevention of joint destruction by tacrolimus in patients with early rheumatoid arthritis: A post hoc analysis of a double-blind, randomized, placebo-controlled study

Yoshiya Tanaka, Shinichi Kawai, Tsutomu Takeuchi, Kazuhiko Yamamoto, Nobuyuki Miyasaka

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Objectives: A multicenter, randomized, double-blind, placebo-controlled study of the oral calcineurin inhibitor tacrolimus was performed in patients with early rheumatoid arthritis who had responded poorly to disease-modifying antirheumatic drugs (DMARDs), and factors related to suppression of joint destruction were investigated. Methods: The change in the total Sharp score (ΔTSS) was assessed by univariate analysis in patients with X-ray films to identify the main determinant of a ΔTSS of <0.5 in week 52. Patients with this factor were then investigated further. Results: Univariate analysis showed that a baseline C-reactive protein (CRP) level of <1.5 mg/dL was the major determinant of ΔTSS <0.5 at week 52 in the tacrolimus group. Detailed analysis of patients with a baseline CRP of <1.5 mg/dL revealed no significant differences in background factors between the two groups. In week 52, ΔTSS was significantly smaller in the tacrolimus group than in the placebo group (2.67 ± 5.40 vs. 8.05 ± 10.32, respectively, p = 0.017). Both groups had a similar incidence of adverse reactions. Conclusions: Adding tacrolimus to DMARDs significantly suppressed disease activity and joint destruction in patients with early rheumatoid arthritis, a disease duration B3 years, a CRP<1.5 mg/dL, and a poor response to oral DMARDs.

Original languageEnglish
Pages (from-to)1045-1052
Number of pages8
JournalModern Rheumatology
Volume23
Issue number6
DOIs
Publication statusPublished - 2013 Nov

Fingerprint

Tacrolimus
Rheumatoid Arthritis
Joints
Placebos
Antirheumatic Agents
C-Reactive Protein
Mouth Diseases
X-Ray Film
Joint Diseases
Incidence

Keywords

  • DMARD
  • Rheumatoid arthritis
  • Tacrolimus

ASJC Scopus subject areas

  • Rheumatology

Cite this

Prevention of joint destruction by tacrolimus in patients with early rheumatoid arthritis : A post hoc analysis of a double-blind, randomized, placebo-controlled study. / Tanaka, Yoshiya; Kawai, Shinichi; Takeuchi, Tsutomu; Yamamoto, Kazuhiko; Miyasaka, Nobuyuki.

In: Modern Rheumatology, Vol. 23, No. 6, 11.2013, p. 1045-1052.

Research output: Contribution to journalArticle

@article{d0d420818fff43c99fb580d49d6eed18,
title = "Prevention of joint destruction by tacrolimus in patients with early rheumatoid arthritis: A post hoc analysis of a double-blind, randomized, placebo-controlled study",
abstract = "Objectives: A multicenter, randomized, double-blind, placebo-controlled study of the oral calcineurin inhibitor tacrolimus was performed in patients with early rheumatoid arthritis who had responded poorly to disease-modifying antirheumatic drugs (DMARDs), and factors related to suppression of joint destruction were investigated. Methods: The change in the total Sharp score (ΔTSS) was assessed by univariate analysis in patients with X-ray films to identify the main determinant of a ΔTSS of <0.5 in week 52. Patients with this factor were then investigated further. Results: Univariate analysis showed that a baseline C-reactive protein (CRP) level of <1.5 mg/dL was the major determinant of ΔTSS <0.5 at week 52 in the tacrolimus group. Detailed analysis of patients with a baseline CRP of <1.5 mg/dL revealed no significant differences in background factors between the two groups. In week 52, ΔTSS was significantly smaller in the tacrolimus group than in the placebo group (2.67 ± 5.40 vs. 8.05 ± 10.32, respectively, p = 0.017). Both groups had a similar incidence of adverse reactions. Conclusions: Adding tacrolimus to DMARDs significantly suppressed disease activity and joint destruction in patients with early rheumatoid arthritis, a disease duration B3 years, a CRP<1.5 mg/dL, and a poor response to oral DMARDs.",
keywords = "DMARD, Rheumatoid arthritis, Tacrolimus",
author = "Yoshiya Tanaka and Shinichi Kawai and Tsutomu Takeuchi and Kazuhiko Yamamoto and Nobuyuki Miyasaka",
year = "2013",
month = "11",
doi = "10.1007/s10165-012-0817-4",
language = "English",
volume = "23",
pages = "1045--1052",
journal = "Modern Rheumatology",
issn = "1439-7595",
publisher = "Springer Japan",
number = "6",

}

TY - JOUR

T1 - Prevention of joint destruction by tacrolimus in patients with early rheumatoid arthritis

T2 - A post hoc analysis of a double-blind, randomized, placebo-controlled study

AU - Tanaka, Yoshiya

AU - Kawai, Shinichi

AU - Takeuchi, Tsutomu

AU - Yamamoto, Kazuhiko

AU - Miyasaka, Nobuyuki

PY - 2013/11

Y1 - 2013/11

N2 - Objectives: A multicenter, randomized, double-blind, placebo-controlled study of the oral calcineurin inhibitor tacrolimus was performed in patients with early rheumatoid arthritis who had responded poorly to disease-modifying antirheumatic drugs (DMARDs), and factors related to suppression of joint destruction were investigated. Methods: The change in the total Sharp score (ΔTSS) was assessed by univariate analysis in patients with X-ray films to identify the main determinant of a ΔTSS of <0.5 in week 52. Patients with this factor were then investigated further. Results: Univariate analysis showed that a baseline C-reactive protein (CRP) level of <1.5 mg/dL was the major determinant of ΔTSS <0.5 at week 52 in the tacrolimus group. Detailed analysis of patients with a baseline CRP of <1.5 mg/dL revealed no significant differences in background factors between the two groups. In week 52, ΔTSS was significantly smaller in the tacrolimus group than in the placebo group (2.67 ± 5.40 vs. 8.05 ± 10.32, respectively, p = 0.017). Both groups had a similar incidence of adverse reactions. Conclusions: Adding tacrolimus to DMARDs significantly suppressed disease activity and joint destruction in patients with early rheumatoid arthritis, a disease duration B3 years, a CRP<1.5 mg/dL, and a poor response to oral DMARDs.

AB - Objectives: A multicenter, randomized, double-blind, placebo-controlled study of the oral calcineurin inhibitor tacrolimus was performed in patients with early rheumatoid arthritis who had responded poorly to disease-modifying antirheumatic drugs (DMARDs), and factors related to suppression of joint destruction were investigated. Methods: The change in the total Sharp score (ΔTSS) was assessed by univariate analysis in patients with X-ray films to identify the main determinant of a ΔTSS of <0.5 in week 52. Patients with this factor were then investigated further. Results: Univariate analysis showed that a baseline C-reactive protein (CRP) level of <1.5 mg/dL was the major determinant of ΔTSS <0.5 at week 52 in the tacrolimus group. Detailed analysis of patients with a baseline CRP of <1.5 mg/dL revealed no significant differences in background factors between the two groups. In week 52, ΔTSS was significantly smaller in the tacrolimus group than in the placebo group (2.67 ± 5.40 vs. 8.05 ± 10.32, respectively, p = 0.017). Both groups had a similar incidence of adverse reactions. Conclusions: Adding tacrolimus to DMARDs significantly suppressed disease activity and joint destruction in patients with early rheumatoid arthritis, a disease duration B3 years, a CRP<1.5 mg/dL, and a poor response to oral DMARDs.

KW - DMARD

KW - Rheumatoid arthritis

KW - Tacrolimus

UR - http://www.scopus.com/inward/record.url?scp=84894366854&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84894366854&partnerID=8YFLogxK

U2 - 10.1007/s10165-012-0817-4

DO - 10.1007/s10165-012-0817-4

M3 - Article

C2 - 23271170

AN - SCOPUS:84894366854

VL - 23

SP - 1045

EP - 1052

JO - Modern Rheumatology

JF - Modern Rheumatology

SN - 1439-7595

IS - 6

ER -